3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
Carboplatin
11
atezolizumab
10
Etoposide
9
durvalumab
6
Topotecan
6
PM 01183
6
Specimen Handling
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Irinotecan
2
Injections
2
Drug Therapy
2
Cisplatin
2
Biopsy
2
AMG 757
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
cabozantinib
1
berzosertib
1
avelumab
1
arginine decarboxylase
1
amrubicin
1
Vaccines
1
Taxes
1
Sodium Chloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
olaparib
×
30 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled